The Journal of Practical Medicine >
Effect of compound Xueshuantong combined with viaminate of oral lichen planus complicated with chronic periodontitis
Received date: 2024-03-22
Online published: 2024-11-19
Objective To investigate the effect of compound Xueshuantong combined with viaminate of oral lichen planus （OLP） complicated with chronic periodontitis （CP）. Methods This study collected 305 patients with OLP and CP and randomly divided them into two groups. There were 156 patients in the observation group and 149 patients in the control group. All patients receive systemic treatment for CP. The control group was treated with viaminate capsules， and the observation group was treated with compound Xueshuantong Capsules combined with viaminate capsules. Both groups were treated for 4 weeks. Clinical efficacy， serum inflammatory factors ［matrix metalloproteinase-3 （MMP-3）， IFN-gamma （IFN-γ）， interleukin 6 （IL-6） and IL-35］， oral mucosal pain Visual Analogue Score （VAS）， lesion area of OLP， periodontal condition， and adverse reactions were detected. Results Compared to the control group， the total effective rate in the observation group was higher （P < 0.05）. After treatment， serum MMP-3 and IL-6 levels， oral mucosal VAS score， lesion area of OLP， gingival index and probing depth all decreased in the two groups （P < 0.05）. The changes of above indicators were more significant in the observation group （P < 0.05）. There was no difference in the incidence of adverse reactions between the two groups （P > 0.05）. Conclusion Compound Xueshuantong combined with viaminate can effectively improve the symptoms of OLP complicated with CP， and alleviate inflammatory reactions， with good therapeutic effects.
Maoqing WANG , Wenhui LI , Meihuang. CAI . Effect of compound Xueshuantong combined with viaminate of oral lichen planus complicated with chronic periodontitis[J]. The Journal of Practical Medicine, 2024 , 40(21) : 3076 -3081 . DOI: 10.3969/j.issn.1006-5725.2024.21.018
| 1 | GONZáLEZ M á， WARNAKULASURIYA S， GONZáLEZ I， et al. Worldwide prevalence of oral lichen planus： A systematic review and meta-analysis［J］. Oral Dis，2021，27（4）：813-828. doi:10.1111/odi.13323 |
| 2 | HOWATI A， THORNHILL M H， COLLEY H E， et al. Immune mechanisms in oral lichen planus［J］. Oral Dis，2023，29（4）：1400-1415. doi:10.1111/odi.14142 |
| 3 | 王佩佩，华飞，黄霞，等. 2型糖尿病伴慢性牙周炎患者的口腔菌群微环境研究进展 ［J］. 实用医学杂志， 2023， 39（10）： 1320-1324. doi:10.3969/j.issn.1006-5725.2023.10.023 |
| 4 | LIU H， CHEN H， LIAO Y， et al. Comparative analyses of the subgingival microbiome in chronic periodontitis patients with and without gingival erosive oral lichen planus based on 16S rRNA gene sequencing［J］. Biomed Res Int，2021，6（27）：992-995. |
| 5 | SANZ M， HERRERA D， KEBSCHULL M， et al. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline［J］. J Clin Periodontol，2020，47（22）：4-60. doi:10.1111/jcpe.13290 |
| 6 | ALSENAID A， ALAMRI A， RUZICKA T， et al. Effective and safe use of alitretinoin after acitretin failure in oral lichen planus［J］. Dermatol Ther，2020，33（6）：14441. doi:10.1111/dth.14441 |
| 7 | 成龙，张传伟，薛俊杰，等. 清脂化瘀方联合复方血栓通片对痰瘀互结型年龄相关性黄斑变性患者的临床疗效［J］. 中成药，2023，45（9）：2901-2906. doi:10.3969/j.issn.1001-1528.2023.09.016 |
| 8 | BAO J， CHEN C， YAN J， et al. Antioxidant therapy for patients with oral lichen planus： A systematic review and meta-analysis［J］. Front Pharmacol，2022，10（13）：1030893. |
| 9 | 中华口腔医学会口腔黏膜病学专业委员会，中华口腔医学会中西医结合专业委员会.口腔扁平苔藓诊疗指南（修订版）［J］. 中华口腔医学杂志，2022，57（2）：115-121. doi:10.3760/cma.j.cn112144-20211115-00505 |
| 10 | 中华口腔医学会牙周病学专业委员会. 重度牙周炎诊断标准及特殊人群牙周病治疗原则的中国专家共识［J］. 中华口腔医学杂志，2017，52（2）：67-71. doi:10.3760/cma.j.issn.1002-0098.2017.02.002 |
| 11 | GUHA P， MOHAN A， KANDASWAMY E. Treatment of periodontitis affecting human primary teeth-a systematic review［J］. Dent J，2023，11（7）：171-174. doi:10.3390/dj11070171 |
| 12 | DOURADO G B， VOLPATO G H， ALMEIDA R R， et al. Likert scale vs visual analog scale for assessing facial pleasantness［J］. Am J Orthod Dentofacial Orthop，2021，160（6）：844-852. doi:10.1016/j.ajodo.2020.05.024 |
| 13 | IGIC M， KOSTIC M， BASIC J， et al. Bleeding index and monocyte chemoattractant protein 1 as gingival inflammation parameters after chemical-mechanical retraction procedure［J］. Med Princ Pract，2020，29（5）：492-498. doi:10.1159/000506878 |
| 14 | SOLDO M， MATIJEVI? J， MAL?I? A， et al. Impact of oral hygiene instructions on plaque index in adolescents［J］. Cent Eur J Public Health，2020，28（2）：103-107. doi:10.21101/cejph.a5066 |
| 15 | BAEZA M， MORALES A， CISTERNA C， et al. Effect of periodontal treatment in patients with periodontitis and diabetes： Systematic review and meta-analysis［J］. J Appl Oral Sci，2020，10（28）：248-252. |
| 16 | SUTTHIBOONYAPAN P， WANG H L， CHARATKULANGKUN O. Flowcharts for easy periodontal diagnosis based on the 2018 new periodontal classification［J］. Clin Adv Periodontics，2020，10（3）： 155-160. doi:10.1002/cap.10095 |
| 17 | YOU Y， HUANG X， CHEN Y， et al. Efficacy and safety of traditional Chinese medicine for erosive oral lichen planus： A protocol for systematic review and meta analysis［J］. Medicine （Baltimore），2020，99（48）：23375. doi:10.1097/md.0000000000023375 |
| 18 | JIANG Y， FENG J， DU J， et al. Clinical and biochemical effect of laser as an adjunct to non-surgical treatment of chronic periodontitis［J］. Oral Dis，2022，28（4）：1042-1057. doi:10.1111/odi.13847 |
| 19 | CAO J， XU M， ZHU L， et al. Viaminate inhibits propionibacterium acnes-induced abnormal proliferation and keratinization of hacat cells by regulating the S100A8/S100A9-MAPK Cascade［J］. Curr Drug Targets，2023，24（13）：1055-1065. doi:10.2174/0113894501243867230928115205 |
| 20 | NABATANZI A， MAFURU M， MALE M， et al. Feasibility study for the long-term management of refractory hyperkeratotic eczema with calcipotriol and betamethasone dipropionate （daivobet?）， viaminate and concomitant conventional therapies： A retrospective study［J］. Clin Cosmet Investig Dermatol，2020，29（13）：789-794. |
| 21 | CAO J， XU M， ZHU L， et al. Viaminate ameliorates Propionibacterium acnes-induced acne via inhibition of the TLR2/NF-κB and MAPK pathways in rats［J］. Naunyn Schmiedebergs Arch Pharmacol，2023，396（7）：1487-1500. doi:10.1007/s00210-022-02379-0 |
| 22 | YAO Y， PAN L， WEI Y， et al. TRIM21 promotes inflammation by ubiquitylating NF-κB in T cells of oral lichen planus［J］. J Oral Pathol Med，2023，52（5）：448-455. doi:10.1111/jop.13428 |
| 23 | DENG J， PAN W， JI N， et al. Cell-Free DNA promotes inflammation in patients with oral lichen planus via the sting pathway［J］. Front Immunol，2022，14（13）：8381-8389. |
| 24 | JURDZI?SKI K T， POTEMPA J， GRABIEC A M. Epigenetic regulation of inflammation in periodontitis： Cellular mechanisms and therapeutic potential［J］. Clin Epigenetics，2020， 12（1）：186-192. doi:10.1186/s13148-020-00982-7 |
| 25 | RAZAVI P， REZAEE S A， AKHONDIAN S， et al. Matrix Metalloproteinase-3 but Not Matrix Metalloproteinase-9， Implicated in the Manifestation of Chronic Periodontitis［J］. Rep Biochem Mol Biol，2023，11（4）：656-662. doi:10.52547/rbmb.11.4.656 |
| 26 | APOLINáRIO G H， APARECIDA A C， FIGUEIREDO K， et al. Specific inhibition of IL-6 receptor attenuates inflammatory bone loss in experimental periodontitis［J］. J Periodontol，2021， 92（10）：1460-1469. doi:10.1002/jper.20-0455 |
| 27 | HO J Y， YEO B S， YANG X L， et al. Local and systemic expression profile of IL-10， IL-17， IL-27， IL-35， and IL-37 in periodontal diseases： A cross-sectional study［J］. J Contemp Dent Pract， 2021，22（1）：73-79. doi:10.5005/jp-journals-10024-3034 |
| 28 | HAN Y， YU C， YU Y， et al. CD25+ B cells produced IL-35 and alleviated local inflammation during experimental periodontitis［J］. Oral Dis，2022，28（8）：2248-2257. doi:10.1111/odi.13939 |
| 29 | WANG F， ZHANG Z. Clinical study on the treatment of oral lichen planus with compound Xueshuantong capsules combined with viaminate ［J］. Drugs Clinic，2021，36（4）：759-762. |
| 30 | ZHOU Q， TU W L， LIU Y. Clinical efficacy and impact on oxidative stress response of compound Xueshuantong combined with Vemectin and Cefacoxime in the treatment of oral lichen planus and chronic periodontitis［J］. J Clinic Rat Drug，2022，15（30）：139-142. |
/
| 〈 |
|
〉 |